S&P 500 Industrials Sector SEC Filings — March 05, 2026

05-03-2026

Hawthorn Bancshares, Inc. (HWBK) filed its 10-K annual report on March 5, 2026, covering the fiscal year ended December 31, 2025, with comparative data for 2024 and 2023 across banking and fiduciary/trust segments. The filing discloses detailed loan portfolio segments including commercial financial/agricultural, real estate construction (residential and commercial), real estate mortgages (residential and commercial), and installment/consumer loans, along with securities holdings, property/equipment, derivatives, and subordinated notes. No specific numerical financial metrics such as revenue growth, declines, or balance sheet totals are provided in the extracted XBRL tags.

• ·Filing covers periods: FY2025 (Jan 1 - Dec 31, 2025), FY2024, FY2023, with some Q4 2025 data.
• ·Loan classifications include Pass, Watch, Special Mention, Substandard, Doubtful; nonperforming and past due receivables tracked by segment.
• ·Securities categories: US Treasury, US Government Agencies/Sponsored Enterprises, States/Political Subdivisions, Mortgage-Backed, Other Debt, Equity.
• ·Trusts issued: Exchange Statutory Trust Two (Mar 17, 2005), Exchange Statutory Trust One (Mar 17, 2004).
• ·Shelf registration referenced as of July 2, 2025; 2025 Repurchase Plan authorized June 5, 2025.

05-03-2026

Pasqal Holding SAS is pursuing a SPAC merger with Bleichroeder Acquisition Corp. II, targeting a Nasdaq listing in 2026 with a $2B valuation, alongside plans for a Euronext Paris IPO in 2026-2027, supported by €340M in funding across two tranches from investors including Parkway, Quanta Computer, LG Electronics, and CMA CGM. The deal positions Pasqal as a French quantum computing unicorn using neutral atom technology, with upcoming Vela machine launch featuring over 250 qubits. However, extensive risks are highlighted, including execution challenges, competition from listed peers like IonQ and IQM ($1.8B valuation), regulatory hurdles, potential shareholder redemptions, and Pasqal's lack of disclosed revenues or operating history.

• ·Pasqal founded in 2019; machines installed in France, Germany, Canada; installations underway in Italy, Saudi Arabia
• ·Promises to double production capacity within 24 months
• ·Nasdaq SPAC expected in 2026; Euronext Paris IPO subject to market conditions in 2026 or 2027
• ·Registration Statement on Form F-4 to be filed with SEC; Bleichroeder Final Prospectus filed Jan 8, 2026; 8-K on Jan 9, 2026

05-03-2026

QuasarEdge Acquisition Corp (QRED), a Cayman Islands-based blank check SPAC with sponsor and management ties to China, filed an S-1 to offer 10 million units at $10 each, raising $100M gross proceeds ($99.5M net before expenses) to be held in trust for an initial business combination. However, the filing highlights substantial risks from potential PRC regulatory uncertainties, which could materially impact operations or security values, and significant dilution to public shareholders ranging from $2.70 to $8.19 per share across redemption scenarios (25% to 100%). The units include ordinary shares (QRED) and rights (QREDR) expected to list on NYSE.

• ·Dilution scenarios as of January 31, 2026: pro forma net tangible book value per share ranges from $5.64 (25% redemptions, over-allotment) to $0.14 (maximum redemptions).
• ·Auditor Simon & Edward, LLP is PCAOB-registered and U.S.-headquartered, mitigating current HFCAA risks but with potential future exposure.
• ·Company qualifies as emerging growth company with reduced reporting requirements.
• ·Over-allotment option could increase units/shares to 11.5M and underwriting to $575K.

05-03-2026

Ranger Energy Services reported full year 2025 revenue of $546.9 million and Adjusted EBITDA of $73.2 million (13.4% margin), down from $78.9 million (13.8%) in 2024, while Q4 2025 revenue increased 10% QoQ to $142.2 million from $128.9 million but declined 1% YoY from $143.1 million, with Q4 Adjusted EBITDA up 21% QoQ to $20.3 million (14.3% margin) yet down 7% YoY from $21.9 million. High Specification Rigs drove growth with Q4 revenue up 14% QoQ and 6% YoY, bolstered by the AWS acquisition, and Processing Solutions revenue rose 22% QoQ; however, Wireline Services revenue plunged 28% QoQ and 45% YoY amid pricing pressures. Free Cash Flow totaled $42.9 million for the year (down from $50.4 million in 2024), supporting share repurchases and dividends exceeding 40% of FCF.

• ·Share repurchases: 994,400 shares at avg $12.26/share in 2025; cumulative 4,320,200 shares at avg $10.80/share since 2023.
• ·Quarterly dividend: $0.06 per share, payable April 6, 2026 (record date March 20, 2026).
• ·Total liquidity Dec 31, 2025: $67.7M (down from $112.1M at Dec 31, 2024).
• ·AWS acquisition funded with ~$22M borrowing, ended year in net cash position.
• ·Contract for 15 additional ECHO rigs: deliveries start Q3 2026, full by end 2027.
• ·Full year 2025 cash from operations: $69.0M (down from $84.5M in 2024).

05-03-2026

Kroger reported fourth quarter FY2025 identical sales without fuel up 2.4% (matching prior year) and full-year up 2.9% (from 1.5%), with adjusted FIFO operating profit of $1.206B (up slightly from $1.174B) and $4.9B (up from $4.7B), and adjusted EPS of $1.28 (up from $1.14) and $4.85 (up from $4.47). However, total sales grew only 1% to $34.7B in Q4 and were flat at $147.6B for the year, GAAP operating profit fell to $1.9B from $3.8B due to $2.5B impairment charges on automated fulfillment network, FIFO gross margin was flat in Q4, and OG&A rate increased 21 basis points in Q4 and 29 basis points for the year. The company completed a $7.5B share repurchase, approved $2B more, appointed Greg Foran as CEO, and guided identical sales without fuel growth of 1.0%-2.0% for FY2026 with adjusted FIFO operating profit of $5.0-$5.2B.

• ·Q4 LIFO charge $11M vs $30M prior year
• ·FY2025 LIFO charge $157M vs $95M prior year
• ·FY2026 guidance: Free Cash Flow $2.7-$2.9B, Cap Ex $3.8-$4.0B, Tax Rate 23%
• ·Identical sales guidance includes 130 basis points unfavorable from Inflation Reduction Act
• ·Q4 ended January 31, 2026

05-03-2026

Greenidge Generation Holdings Inc. reported preliminary Q4 2025 revenue of $11.5M, down $3.7M QoQ from Q3, with net income of $1.9-2.9M also declining $9.1-10.1M QoQ, though power and capacity revenue improved $0.8M QoQ to $5.6M. For FY 2025, total revenue was $58.8M, slightly down $0.8M YoY, but net income improved $24.0-25.0M YoY to $4.2-5.2M amid debt reduction from $68.5M to $36.7M and strategic progress including 100MW power approvals and NYSDEC agreement for Dresden Title V permit renewal. Bitcoin production fell to 53 in Q4 (down 42 QoQ) and 371 for FY (down 570 YoY), reflecting mixed transition to AI/HPC datacenters.

• ·Secured 60MW non-curtailable power at Dresden via grid interconnection and 40MW at Mississippi greenfield site by Q1 2027.
• ·Initiated NYISO study for additional 200MW at Dresden.
• ·Agreement with NYSDEC ensures Title V permit renewal post-public comment, compliant with NY Climate Leadership Community Protection Act.
• ·Extended C-Pond closure deadline to Oct 2027; testing at Lockwood Landfill in Q2 2026.
• ·Senior unsecured debt reduced from $157.5M in 2023 to $39.0M as of Dec 31, 2025.

05-03-2026

Granite Ridge Resources, Inc. reported Q4 2025 total production up 27% YoY to 35,120 Boe/day (49% oil) and full-year production up 28% to 31,984 Boe/day, with Adjusted EBITDAX of $69.5M in Q4 and $315.0M for the year; however, it posted a Q4 net loss of $25.1M due to non-cash items, and lease operating expenses rose 29% per Boe YoY to $7.72/Boe. Proved reserves grew 15% to 62,347 MBoe, supported by acquisitions and extensions, while 2026 guidance projects 34,000-36,000 Boe/day (midpoint +9% YoY). The company invested $127.5M in Q4 capital expenditures and ended with $339.5M liquidity and 1.2x Net Debt to Adjusted EBITDAX.

• ·Q4 realized oil price $55.49/Bbl (92% of WTI at $59.64/Bbl); natural gas $1.81/Mcf (48% of Henry Hub at $3.75/Mcf).
• ·Production and ad valorem taxes 5.9% of sales in Q4 (6.1% full-year).
• ·G&A costs $8.0M in Q4 ($31.0M full-year), including non-cash stock-based comp.
• ·2026 guidance: acquisitions $20-30M, D&C capex $300-330M, total capex $320-360M, LOE $6.75-7.75/Boe, taxes 6-7% of revenue, cash G&A $25-27M.
• ·Conference call: March 6, 2026 at 10:00 AM CT; Piper Sandler Energy Conference: March 17, 2026.

05-03-2026

Gevo reported full-year 2025 revenue of $161 million, up dramatically from $17 million in 2024, fueled by record low-carbon ethanol production of 69 million gallons (+3% YoY) and $52 million in production tax credit sales. Fourth-quarter highlights included positive cash flow from operations of $20 million, Adjusted EBITDA of $7.7 million (third consecutive positive quarter), and total cash position of $117 million (up $9 million from prior quarter); however, the company posted a Q4 operating loss of $2.2 million. Strategic progress included the January 2025 acquisition of Red Trail Energy assets (now Gevo North Dakota), debt consolidation in February 2026 releasing restricted cash, and advancements in SAF projects and carbon credits monetization of 140,000 tons.

• ·Gevo North Dakota CCS asset certified by Puro.Earth as thousand-year permanence well and received 'A' rating from BeZero Carbon.
• ·U.S. DOE EDF loan guarantee conditional commitment extended for potential ATJ SAF project financing.
• ·Luverne facility divestiture expected to save $3M in costs in 2026.
• ·Secured multi-year offtake for CDR credits and contracted Scope 1/3 credits for 15M gallons/year future SAF production.
• ·Total assets increased to $719M at YE2025 from $584M at YE2024.

05-03-2026

On March 3, 2026, the Board of Directors of Acadia Pharmaceuticals Inc. appointed Jonathan M. Poole as a Class II director to fill a vacancy and as a member of the Audit Committee, effective immediately, with his term expiring at the 2027 Annual Meeting of Stockholders. Pursuant to the Non-Employee Director Compensation Policy, Mr. Poole will receive prorated annual cash retainers of $50,000 for Board service and $12,500 for Audit Committee service. He also received an initial equity grant under the 2024 Equity Incentive Plan with $200,000 target fair value and a prorated annual grant of $95,300 target fair value, with future annual grants set at $400,000 target fair value.

• ·Equity grants divided equally between nonstatutory stock options and restricted stock units; initial grant vests over three years, prorated grants vest over one year or at next annual meeting.
• ·No arrangements or understandings pursuant to which Mr. Poole was selected as director.
• ·No related person transactions required to be disclosed under Item 404(a) of Regulation S-K.

05-03-2026

Brand Engagement Network Inc. (BEN) completed the closing of its previously announced AI licensing partnership with Valio Technologies (Pty) Ltd on March 4, 2026, which includes a $2.05 million AI licensing agreement and the establishment of Skye Africa Intelligence Pty Ltd to deploy BEN’s conversational AI technologies in select African markets. Tyler Luck, BEN’s Chief Executive Officer and Co-Founder, was appointed to the Board of Directors of Skye Africa Intelligence Pty Ltd on behalf of the Company. No negative financial impacts or declines were reported in this amendment to the original January 21, 2026 announcement.

• ·Originally announced on January 21, 2026
• ·Form 8-K/A filed on March 5, 2026

05-03-2026

Moderna, Inc. entered into a Settlement Agreement on March 3, 2026, with Arbutus Biopharma Corporation and Genevant Sciences entities, resolving all worldwide patent infringement litigation related to Spikevax® and mRESVIA®, while securing a fully paid-up, royalty-free license for its infectious disease portfolio including mNEXSPIKE® and mCOMBRIAX®. The agreement requires a $950M noncontingent payment by July 8, 2026, and a potential additional $1.3B contingent payment based on the outcome of Moderna's appeal to the Federal Circuit regarding §1498 defenses for U.S. Government contract doses, providing litigation certainty but at a substantial near-term cost.

• ·Settlement includes mutual releases and covenants not to sue on Arbutus/Genevant patents for Moderna’s SM-102-based LNP infectious disease vaccines.
• ·If Moderna prevails fully on §1498 appeal, no contingent payment due; if affirmed against Moderna, full $1.3B due; Arbutus/Genevant must repay with interest if later overturned.
• ·Full Settlement Agreement to be filed as exhibit to Q1 2026 10-Q.

05-03-2026

Baytex Energy Corp. filed its Form 40-F annual report for the fiscal year ended December 31, 2025, incorporating the Annual Information Form, audited consolidated financial statements, MD&A, and supplemental oil and gas disclosures. The company reported 765,568,147 common shares outstanding at year-end, with effective disclosure controls and procedures and no material changes in internal controls over financial reporting. No specific financial performance metrics or period-over-period changes were detailed in the provided filing content.

• ·Filing date: March 05, 2026
• ·Fiscal year end: December 31, 2025
• ·Common shares trade on NYSE under symbol BTE
• ·Cash generating units include Viking and Lloydminster
• ·Disclosure controls and procedures confirmed effective as of December 31, 2025
• ·No changes in internal control over financial reporting during FY2025

05-03-2026

SandRidge Energy reported strong full-year 2025 production growth to 18.5 MBoe/d (+12% YoY Boe basis, +32% oil) driven by Cherokee acquisition and development, achieving adjusted EBITDA of $101.1M and proved reserves of 69.1 MMBoe (+10% YoY). However, realized commodity prices declined notably (oil $63.64/Bbl, -14% YoY), resulting in Q4 revenues of $39.4M (flat vs Q3 2025 and slightly up vs Q4 2024) and adjusted net income down 19% QoQ to $12.5M. The Board declared a $0.12/share cash dividend payable March 31, 2026, and issued 2026 guidance for 6.4-7.7 MMBoe production with $76-97M capex.

• ·Q4 2025 LOE $4.34/Boe, down from $6.43/Boe Q4 2024 due to non-recurring adjustments
• ·2026 guidance: LOE $39-47M, Adjusted G&A $10-12M, Oil production 1.2-1.7 MMBbls
• ·$68.3M remaining share repurchase authorization as of Dec 31, 2025
• ·Over four years without a recordable safety incident as of 2025

05-03-2026

Shattuck Labs, Inc. reported total revenue of $1M for the year ended December 31, 2025, down 82.5% from $5.7M in 2024 primarily due to the absence of $5.7M in collaboration revenue. Research and development expenses decreased 47.5% to $35.3M, while general and administrative expenses fell 9.7% to $17.2M, resulting in a narrower net loss of $48.8M (35.3% improvement) compared to $75.4M in 2024. Cash and equivalents ended at $54.2M after a modest $3.2M decrease, bolstered by $44.6M in financing activities from stock sales.

• ·Cash and equivalents decreased $3.2M to $54.2M in 2025 vs $68.2M decrease to $57.4M in 2024.
• ·Shares outstanding increased to 63.3M from 47.7M due to $44.5M stock offering.
• ·Total assets stable at $91.0M; stockholders' equity rose to $82.4M from $79.6M.
• ·Net cash used in operating activities improved to $39.9M from $60.5M.

05-03-2026

On March 5, 2026, Philip Morris International Inc. announced via press release that its Board of Directors declared a regular quarterly dividend of $1.47 per common share. The announcement is furnished under Item 7.01 and not deemed filed for liability purposes. The filing also lists the company's registered securities, including common stock (PM) and multiple series of notes with maturities from 2026 to 2044.

• ·Filing submitted by Darlene Quashie Henry on behalf of Philip Morris International Inc.
• ·Principal executive offices: 677 Washington Blvd, Ste. 1100, Stamford, Connecticut 06901.
• ·Telephone: (203) 905-2410.

05-03-2026

Lexicon Pharmaceuticals reported Q4 2025 revenues of $5.5M, down 79% YoY from $26.6M due to lower licensing revenue, while full-year revenues increased 60% YoY to $49.8M driven by $45M Novo Nordisk upfront; net product sales of INPEFA declined 23% YoY to $4.6M for the year. R&D and SG&A expenses decreased significantly (28% and 74% YoY for full year), narrowing full-year net loss to $50.3M from $200.4M, but cash position fell to $125.2M from $238M as of Dec 31, 2025, bolstered post-period by over $100M from capital raise and Novo milestone. Pipeline advanced with sotagliflozin HCM enrollment over 50%, T1D NDA resubmission on track for 2026, and positive FDA meeting for pilavapadin Phase 3.

• ·SONATA-HCM enrollment surpassed 50%, completion mid-2026, topline Q1 2027.
• ·Pilavapadin End-of-Phase 2 FDA meeting successful; Phase 3 to include two 12-week studies with 10mg dose, primary endpoint change in average daily pain score.
• ·LX9851 IND-enabling activities completed; $10M Novo milestone received Feb 2026, up to $20M more in 2026.
• ·Viatris shipped first commercial sotagliflozin to UAE; submissions in Canada, Australia, New Zealand.

05-03-2026

Bank of New York Mellon Corp's 2026 DEF 14A proxy statement seeks advisory approval of 2025 NEO compensation, emphasizing strong performance under CEO Robin Vince with annualized adjusted revenue growth of 6%, noninterest expense growth of 3%, and operating EPS growth of 18% from 2022-2025, resulting in 178% total shareholder return outperforming the S&P 500 Financials Index by over 2.5x. Prior three-year say-on-pay proposals received average 95% stockholder support. No declines or flat metrics were highlighted in the disclosed performance data.

• ·Compensation for Mses. O’Connor and Robinson includes amounts for roles as Chair and member of the Board of BNY Mellon Government Securities Services Corp.
• ·Proxy seeks approval pursuant to Item 402 of Regulation S-K.

05-03-2026

REGENXBIO reported Q4 2025 revenues of $30.3M, up 43% YoY from $21.2M, and full-year 2025 revenues of $170.4M, up 105% YoY from $83.3M, driven by Nippon Shinyaku collaboration and higher royalties; however, Q4 net loss widened 31% YoY to $67.1M from $51.2M due to elevated R&D expenses (up 18% to $59.6M) and G&A (up 11% to $22.4M), while full-year net loss improved 15% to $193.9M from $227.1M. Cash and equivalents declined slightly 2% YoY to $240.9M from $244.9M, funding operations into early 2027, amid pipeline progress like RGX-202 data in Q2 2026 but setbacks including FDA holds on RGX-111/RGX-121 and a CRL for RGX-121.

• ·RGX-202 Phase I/II patients (n=4) improved average 7.4 NSAA points vs cTAP at 18 months (up from 6.6 at 12 months).
• ·ALTITUDE trial Dose Level 3 (n=15): 50% achieved ≥2-step DRSS improvement at 2 years; ≥70% risk reduction in vision-threatening complications vs historical controls.
• ·Pivotal enrollment complete for RGX-202 (n=30) in Oct 2025; confirmatory trial (n=30) ongoing.
• ·FDA clinical holds on RGX-111 (neoplasm case) and RGX-121 in Jan 2026; CRL for RGX-121 BLA in Feb 2026.
• ·Company plans FDA engagement on RGX-121 path forward; pre-BLA meeting mid-2026.

05-03-2026

Delta Air Lines announces key leadership changes, including Peter Carter's promotion to President, Dan Janki's appointment as Chief Operating Officer (previously CFO), Erik Snell's move to Chief Financial Officer, Ranjan Goswami's naming as Chief Marketing and Product Officer, and Alain Bellemare adding Chairman of Delta TechOps to his role as EVP and President – International. These changes follow the retirement of John Laughter, longtime EVP Chief of Operations and President of Delta TechOps, effective April 30, 2026, after over 30 years, and Alicia Tillman's departure as Chief Marketing Officer for external opportunities. CEO Ed Bastian emphasized the moves strengthen the executive team and reflect Delta's deep talent bench to drive long-term growth.

• ·All new appointees (Carter, Janki, Snell, Goswami) report directly to CEO Ed Bastian.
• ·John Laughter's career started as an aircraft liaison engineer in TechOps.

05-03-2026

Reviva Pharmaceuticals Holdings, Inc. amended its Amended and Restated Certificate of Incorporation to implement a one-for-20 reverse stock split of its Common Stock, effective 12:01 a.m. Eastern Time on March 9, 2026. The Reverse Split reclassifies every 20 shares of Old Common Stock into 1 share of New Common Stock, with no reduction in authorized shares, and applies to convertible securities or rights. The amendment was duly adopted by the Board of Directors and stockholders per Delaware General Corporation Law, with fractional shares rounded up to the nearest whole share.

• ·Reverse Split executed on March 4, 2026, and filed on March 5, 2026.
• ·Old Common Stock certificates automatically represent New Common Stock post-Effective Time, subject to fractional adjustment.
• ·Reverse Split applies to securities or rights convertible into, exchangeable for, or exercisable for Old Common Stock.

05-03-2026

Splash Beverage Group, Inc. announced the execution of a non-binding letter of intent for a business combination with Medterra CBD, LLC, a leading manufacturer and multi-brand operator of federally compliant cannabinoid wellness products. Medterra serves over 2 million customers across the United States and internationally. The press release detailing the LOI is furnished as Exhibit 99.1.

• ·The letter of intent is non-binding.
• ·Announcement date: March 5, 2026.

05-03-2026

Global Payments Inc. filed this 8-K on March 5, 2026, to provide audited combined and consolidated financial statements of Worldpay Holdco, LLC (acquired 100% in January 2026 from Fidelity National Information Services, Inc. and GTCR LLC affiliates) as of December 31, 2025 and 2024, for the year ended December 31, 2025, the eleven-month period ended December 31, 2024 (Successor), and the one-month period ended January 31, 2024 (Predecessor). The filing also includes unaudited pro forma condensed combined financial information for Global Payments as of and for the year ended December 31, 2025, following the simultaneous divestiture of its Issuer Solutions business to FIS. This updates investors on the financial data related to these transactions for incorporation into registration statements.

• ·Securities registered: Common stock (GPN) and 4.875% Senior Notes due 2031 (GPN31A) on New York Stock Exchange.
• ·Consent of KPMG LLP provided for Worldpay financial statements.

05-03-2026

On February 27, 2026, Valerie O. Murray, President of Beacon Trust Company and Executive Vice President and Chief Wealth Management Officer of Provident Bank (subsidiaries of Provident Financial Services, Inc.), announced her resignation effective May 22, 2026, to pursue other opportunities, with no disagreement on company matters. Under the Separation Agreement, she will be on garden leave from March 27 to May 22, 2026, continuing to receive base salary and benefits, and is entitled to a $1.2M lump sum payment subject to conditions including a release of claims. The company expressed appreciation for her leadership and contributions.

• ·Filing date: March 5, 2026
• ·Garden leave period: March 27, 2026 to May 22, 2026
• ·Resignation announcement date: February 27, 2026

05-03-2026

AGCO CORP filed an 8-K on March 05, 2026, under Items 5.02 (Director/Officer Departure/Election) and 9.01 (Financial Statements and Exhibits), announcing an officer or director change with an attached press release (EX-99.1). The content details are largely unreadable due to formatting issues, providing no specific names, roles, or financial impacts. No quantitative metrics or period-over-period comparisons are discernible.

• ·Filing Type: 8-K
• ·Subcategory: Director/Officer Departure/Election

05-03-2026

Decoy Therapeutics Inc., originally incorporated as Flex Pharma, Inc. on February 26, 2014, amended its Certificate of Incorporation to authorize 110M total shares (100M Common Stock and 10M Preferred Stock, each with $0.0001 par value) and effected a 1-for-12 reverse stock split without changing authorized share totals. The reverse split consolidates every 12 old shares into 1 new share effective 5:00 p.m. ET on March 6, 2026, with cash payments in lieu of fractional shares based on the Nasdaq closing price. No performance metrics or financial changes are reported.

05-03-2026

OFG Bancorp filed Amendment No. 1 to its 10-K for the fiscal year ended December 31, 2025, solely to correct the cover page checkbox for well-known seasoned issuer status (now marked No) and to add Sarbanes-Oxley certifications as exhibits. No changes were made to financial statements, disclosures, or other content from the original filing on February 25, 2026. The aggregate market value of common stock held by non-affiliates was $1.915B as of June 30, 2025, based on 44,741,933 shares at $42.80 per share.

• ·Registrant is a large accelerated filer but not a well-known seasoned issuer.
• ·Incorporated in Commonwealth of Puerto Rico (EIN: 66-0538893); principal offices at 254 Muñoz Rivera Avenue, San Juan, Puerto Rico 00918.
• ·Common shares ($1.00 par value) trade on NYSE under symbol OFG.
• ·Original 10-K filed February 25, 2026; amendment filed March 5, 2026.

05-03-2026

Global Crossing Airlines Group Inc. reported total revenue growth of 10.1% YoY to $246.3M for the year ended December 31, 2025, driven by ACMI revenue surging 42.8% to $175.8M, while Charter revenue declined sharply 34.8% to $62.3M and total Charter block hours fell 39.6%. Operating income improved to a positive $8.9M from a $1.1M loss, with operating expenses up only 5.6% to $237.4M despite rises in salaries (18.8%) and maintenance (44.7%), but the company recorded a net loss of $2.6M (improved from $11.4M) amid higher interest expense (28.5%). Cash from operations rose significantly to $28.1M, supporting total assets of $203.1M up from $166.7M.

• ·Cash and cash equivalents increased to $16.7M from $12.3M as of Dec 31, 2025.
• ·Stockholders’ deficit remained relatively flat at approximately $29.5M.
• ·Total block hours grew 16.5% to 33,564.
• ·Aircraft rent expense nearly flat at $57.4M (-0.4%).
• ·Loss per share improved to $(0.05) from $(0.19).

05-03-2026

Valhi, Inc. (VHI) filed an 8-K on March 5, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01, furnishing a press release entitled 'Valhi Declares Quarterly Dividend' issued the same day, attached as Exhibit 99.1. The filing incorporates the press release by reference but notes it is not 'filed' for liability purposes under Section 18 of the Exchange Act.

05-03-2026

Carter Bankshares, Inc. reported net interest income growth of 14.3% YoY to $130.8M in 2025 from $114.5M in 2024, with net interest margin expanding to 2.82% from 2.57% and average earning assets rising to $4.64B. Loan portfolio averaged $3.76B, up from $3.56B, driven by commercial real estate and construction loans. However, noninterest expenses increased 6.4% to $117.1M, outpacing 4.8% growth in noninterest income to $22.4M, while insurance commissions declined 26.0% and total liquidity sources fell to $1.23B from $1.39B.

• ·Highly Liquid Assets to Uninsured Deposits declined to 59.8% in 2025 from 66.8% in 2024.
• ·Federal Home Loan Bank Borrowings decreased to $110.9M average in 2025 from $222.7M in 2024.
• ·Pretax Net Interest Income sensitivity: +200 bps change results in -1.0% impact in 2025.

05-03-2026

Home BancShares, Inc. (HOMB) reported record 2025 financial results, including total loans of $15.7B, stockholders' equity of $4.3B, net income of $475M (ROAA 2.10%), and diluted EPS of $2.41. The company announced the acquisition of Mountain Commerce Bancorp, Inc. (MCBI) on December 8, 2025, expected to close in Q2 2026, providing entry into Tennessee markets including Knoxville, Nashville, and Johnson City. West Texas operations have improved post-Happy State Bank acquisition, with no ongoing legal expenses, while total shareholder return since 2006 turned a $1,000 investment into $24,581.

• ·Net Interest Margin: 4.51%
• ·Efficiency Ratio: 40.88%
• ·Tangible Book Value per Share (non-GAAP): $14.60
• ·Dividends per Share: $0.805
• ·Shareholders’ Meeting: April 16, 2026
• ·MCBI acquisition expected to be immediately triple accretive

05-03-2026

Twin Vee PowerCats Co. (VEEE) filed an S-3/A amendment to its shelf registration statement (No. 333-292661) on March 5, 2026, to register potential future issuances of common stock, preferred stock, debt securities, warrants, and related instruments. The filing lists various incorporated exhibits, including forms of warrants from prior 8-Ks, a specimen preferred stock certificate, indenture forms, legal opinions, and auditor consents. It was signed by CEO Joseph C. Visconti and directors in Ft. Pierce, Florida.

• ·File No. 001-40623
• ·Incorporated exhibits reference prior filings: March 31, 2022; September 30, 2022; August 16, 2022; June 14, 2023; May 12, 2025; February 23, 2026
• ·Legal counsel: Sichenzia Ross Ference Carmel LLP
• ·Auditor: Grassi & Co., CPAs, P.C.

05-03-2026

Quest Water Global, Inc. (QWTR) reported a significantly larger net loss of $291,413 for the three months ended September 30, 2025, compared to $137,329 in the prior year (112% YoY increase), driven by new marketing expenses and higher management fees. For the nine months ended September 30, 2025, the net loss edged up 3.4% YoY to $630,907 from $610,054, while total expenses rose modestly to $630,907. Stockholders' deficit widened to $2.94M from $2.26M YoY amid continued cash burn from operations funded by related party advances.

• ·Management fees for nine months ended Sep 30, 2025: $401,250 (up from $371,250 YoY)
• ·Stock-based compensation: $99,200 in Q3 2025 (nine months total includes prior periods)
• ·Cash and equivalents end of nine months: $9 (down from $12 YoY)
• ·Computer equipment fully depreciated to $0 net book value as of Sep 30, 2025

05-03-2026

NCS Multistage Holdings, Inc. reported total revenues of $183.6M for the year ended December 31, 2025, up 13.0% YoY from $162.6M, driven by strong U.S. growth of 33.5% but tempered by modest 4.7% growth in Canada. Net income rose 219.9% to $26.0M, boosted by a $9.2M tax benefit, while operating income increased 143.7% to $10.5M; however, services gross margin declined to 45.0% from 48.7%, and other countries services revenues fell 31.1% YoY.

• ·Net cash provided by operating activities increased to $22.2M in 2025 from $12.7M in 2024.
• ·U.S. services revenues surged 87.8% YoY to $18.0M.
• ·Product sales revenues grew 13.1% YoY to $127.9M, with Other Countries up 126.1%.
• ·Provision for litigation of $0.9M in 2025.
• ·Filing date: March 05, 2026 for year ended December 31, 2025.

05-03-2026

Traeger, Inc. reported FY 2025 total revenues of $559.5 million, down 7.4% YoY from $604.1 million but above the high end of guidance, driven by consumables growth of 6.9% to $127.5 million while grills fell 8.2% to $298.0 million and accessories declined 16.3% to $134.0 million. Q4 revenues dropped 13.8% to $145.4 million, with grills down 22.3% and accessories down 17.9%, though consumables rose 15.8% and Adjusted EBITDA improved 5.4% to $19.4 million; FY Adjusted EBITDA decreased 14.5% to $70.0 million amid a $74.7 million goodwill impairment. Project Gravity is on track for $64-70 million in annualized savings by end-2026, with FY 2026 guidance for revenues of $465-485 million and Adjusted EBITDA of $50-60 million.

• ·North America revenues decreased 5.1% YoY in FY 2025 and 13.0% in Q4 2025; Rest of World down 27.3% FY and 21.6% Q4.
• ·FY 2026 guidance: Q1 revenues $92-97M, Adjusted EBITDA $3-7M; Free Cash Flow at least $30M.
• ·Cash and cash equivalents $19.6M (up from $15.0M); Inventory $98.8M (down from $107.4M) at Dec 31, 2025.
• ·Restructuring costs: $21.8M FY 2025, $12.2M Q4 2025 related to Project Gravity.

05-03-2026

RTX Corporation announced that director James A. Winnefeld Jr. resigned effective March 5, 2026, with no dispute or disagreement regarding company operations, policies, or practices. As a result, the Board size will decrease from 11 to 10 members.

05-03-2026

Guidewire Software reported Q2 FY2026 total revenue of $359.1M, up 24% YoY, driven by 33% growth in subscription and support revenue to $237.2M and 30% increase in services revenue to $62.4M; however, license revenue declined 7% YoY to $59.5M. ARR reached $1.121B, reflecting 22% YoY growth, with strong profitability including GAAP operating income of $38.4M (vs $11.7M prior) and the company raising its FY2026 outlook across key metrics. Cash and equivalents decreased to $1.351B from $1.483B at prior quarter-end amid share repurchases.

• ·GAAP net income $60.1M in Q2 FY2026 vs net loss of $37.3M in Q2 FY2025.
• ·Non-GAAP diluted EPS $1.17 in Q2 FY2026 vs $0.51 prior year.
• ·Q3 FY2026 outlook: Total revenue $352M-$358M; FY2026 total revenue $1.438B-$1.448B.
• ·FY2026 operating cash flow outlook $360M-$375M.

05-03-2026

EyePoint Pharmaceuticals reported total revenues of $31.4M for FY 2025, down 28% YoY from $43.3M, with product sales declining 50% to $1.6M and license/collaboration revenues dropping 57% to $16.7M, though royalty income surged 708% to $13.0M. Operating expenses rose 45% to $274.8M, primarily due to a 66% increase in R&D to $221.0M, resulting in a net loss of $232.0M, up 77% from $130.9M in FY 2024. Cash and equivalents stood at $101.8M as of Dec 31, 2025, with net cash used in operations worsening to $240.1M and stockholders' equity declining to $306.1M.

• ·Marketable securities decreased to $204.3M from $271.2M as of Dec 31, 2025.
• ·Total current assets down to $328.7M from $383.3M.
• ·Stock-based compensation expense $27.9M in FY 2025 vs $36.7M in FY 2024.
• ·Issuance of common stock net of costs: 13.7M shares raising $172.9M in FY 2025.

05-03-2026

Iridium Communications Inc. declared a cash dividend of $0.15 per share on its common stock, payable on March 31, 2026, to stockholders of record as of March 16, 2026. The Board of Directors approved the dividend on March 5, 2026. No comparative financial metrics or prior period data were disclosed.

• ·Filing submitted pursuant to Item 7.01 Regulation FD Disclosure.

05-03-2026

Bridger Aerospace reported record 2025 full-year revenue of $122.8 million, up 25% YoY from $98.6 million, Adjusted EBITDA of $45.3 million (+21% YoY), and positive net income of $4.1 million versus a $15.6 million loss in 2024. However, Q4 2025 revenue fell 45% YoY to $8.5 million from $15.6 million, with a widened net loss of $15.1 million (vs. $12.8 million) and Adjusted EBITDA of negative $9.5 million (vs. negative $2.9 million). The company completed a $331.5 million financing package including a $100 million delayed draw facility and initiated 2026 guidance of $135-145 million revenue (10-18% growth at midpoint) and $55-60 million Adjusted EBITDA.

• ·Cost of revenues increased to $71.1M in 2025 from $57.5M in 2024.
• ·SG&A expenses rose to $13.4M in Q4 2025 from $7.7M in Q4 2024.
• ·Added first two Spanish Scoopers and four additional air surveillance aircraft.
• ·2026 guidance excludes $14.0M non-recurring return to service revenue from 2025.

05-03-2026

aTyr Pharma reported FY 2025 net loss of $74.1M, worsening 16% YoY from $64.0M due to increased R&D expenses ($60.2M, +11% YoY) and G&A ($17.6M, +28% YoY), with revenues declining to $0.190M from $0.235M. Cash position improved to $80.9M from $75.1M, providing runway for ongoing programs. Phase 3 EFZO-FIT™ missed primary endpoint of corticosteroid reduction but showed statistical benefits in secondary measures like KSQ-Lung (p=0.0479); FDA meeting set for mid-April 2026, while Phase 2 EFZO-CONNECT™ enrollment remains on track for H1 2026.

• ·Phase 3 EFZO-FIT™ evaluated 3.0 mg/kg and 5.0 mg/kg efzofitimod vs placebo; primary endpoint missed (change in mean daily oral corticosteroid dose at week 48).
• ·Secondary benefits at 5.0 mg/kg: KSQ-Lung (p=0.0479), Fatigue Assessment Scale (p=0.0226), KSQ-General Health (p=0.0197), complete steroid withdrawal with KSQ-Lung improvement (p=0.0196).
• ·Phase 2 EFZO-CONNECT™: 2:2:1 randomization to 270 mg, 450 mg efzofitimod or placebo IV monthly for 6 doses.

05-03-2026

Pattern Group Inc. reported record FY2025 revenues of $2.5B, up 39% YoY from $1.8B, with Q4 revenues reaching $723M, up 40% YoY, alongside record NRR of 124% (up from 116%), non-Amazon revenue of $183M (up 60%), and international revenue of $266M (up 63%). Adjusted EBITDA rose 52% YoY to $153M, and net cash from operations increased 41% to $99M. However, GAAP net income declined 76% to $16M from $68M due to $104M in stock-based compensation and IPO-related costs, with operating income falling 71% to $25M and FY EPS at $(1.36). The company announced a $100M share repurchase program.

• ·Total assets increased to $948M as of Dec 31, 2025 from $664M at end of 2024.
• ·Inventory grew to $295M as of Dec 31, 2025 from $264M.
• ·Q1 2026 Revenue guidance: $710M to $720M (31-33% YoY growth).
• ·Q1 2026 Adjusted EBITDA guidance: $41M to $42M (22-24% YoY growth).
• ·Acquired business for $19M net of cash in 2025.

05-03-2026

Phio Pharmaceuticals reported increased operating expenses of $9.22M for 2025 (up 24.8% YoY from $7.39M), driven by R&D (+26.8% to $4.62M) and G&A (+22.9% to $4.60M), resulting in a wider net loss of $8.70M (up 21.7% YoY from $7.15M). However, strong financing activities provided $23.64M in net cash, boosting cash and equivalents to $21.03M (up 290.9% from $5.38M) and total assets to $21.49M. Common shares outstanding surged to 11.62M from 1.73M due to issuances and warrant exercises.

• ·Net cash used in operating activities increased to $7.98M in 2025 from $7.11M in 2024.
• ·Interest income, net was $0.52M in 2025 vs $0.23M in 2024.
• ·Diluted net loss per share improved to $(1.45) in 2025 from $(9.08) in 2024 due to increased share count.
• ·Stock-based compensation expense was $0.48M in 2025 vs $0.15M in 2024.
• ·Offering costs for common stock and warrants issuance in 2025 totaled $2.9M.

05-03-2026

ArriVent BioPharma reported a significantly widened net loss of $166.3M for the year ended December 31, 2025, up 107% from $80.5M in 2024, primarily due to R&D expenses nearly doubling to $153.4M (+94%) and G&A rising 58% to $24.2M. While total assets increased 21% to $333.2M bolstered by $203.1M in financing inflows and short-term investments growing to $267.3M, cash and equivalents declined 39% to $45.5M amid heightened operating cash burn of $160.6M. Interest income also decreased 19% to $11.2M.

• ·Accumulated deficit increased to $404.6M as of Dec 31 2025 from $238.3M as of Dec 31 2024.
• ·Short-term investments rose to $267.3M as of Dec 31 2025 from $144.6M as of Dec 31 2024.
• ·Financing activities provided $203.1M in 2025 vs $186.6M in 2024.
• ·Investing activities used $71.2M in cash in 2025 vs $192.5M in 2024.

05-03-2026

Entravision Communications Corp reported consolidated net revenue of $447.6M for the year ended December 31, 2025, up 23% YoY from $365.0M, driven by explosive 90% growth in Advertising Technology & Services to $270.9M; however, Media revenue declined 20% to $176.7M and direct operating expenses for that segment were nearly flat at $109.6M. Operating loss widened 60% to $83.4M from $52.0M, impacted by a $55.4M impairment charge, $25.2M loss on lease abandonment, and $2.8M restructuring costs, resulting in a net loss of $79.2M that improved from $148.9M in 2024 but remained negative with EPS of $(0.87). Cash and equivalents fell to $59.4M from $95.9M, total assets decreased to $387.5M, and stockholders' equity dropped to $55.4M from $146.0M.

• ·Cash flow from operating activities $10.6M in 2025, down from $74.7M in 2024.
• ·Capital expenditures $6.8M in 2025 vs $7.5M in 2024.
• ·Dividends declared $0.20 per common share in 2025, unchanged from prior years.
• ·Basic and diluted EPS $(0.87) in 2025 vs $(1.66) in 2024.
• ·Net cash used in financing activities $41.0M in 2025.

05-03-2026

BBOT reported Q4 and FY 2025 financial results with cash and equivalents of $425.5M, providing runway into 2028, and highlighted positive preliminary clinical data including 65% ORR for BBO-8520 monotherapy in KRASG12C NSCLC and a confirmed PR in PDAC for BBO-11818. However, net loss widened to $38.8M in Q4 2025 (up ~97% YoY) and $134.0M for FY 2025 (up ~80% YoY), driven by R&D expenses rising 95% to $38.1M in Q4 and 66% to $121.2M for the year due to clinical and manufacturing costs. Updated data readouts across all three programs are expected in H2 2026.

• ·BBO-8520 received FDA Fast Track designation on January 9, 2025 for KRASG12C mutated metastatic NSCLC.
• ·83% of BBO-8520 monotherapy patients eligible for 6-month follow-up remained on treatment ≥6 months.
• ·BBO-11818 showed 56% tumor reduction in PDAC patient with confirmed PR.
• ·BBO-10203 showed no hyperglycemia and full target engagement in Phase 1 trial.

05-03-2026

Total revenues grew 53% YoY to $14.6M in 2025 from $9.5M in 2024, driven by collaboration revenues surging 67% to $13.6M, though royalties, license and other revenues declined 30% to $0.9M. Operating expenses increased 65% to $51.2M, including a $14.8M impairment of intangible assets and R&D up 42% to $17.7M, while G&A was nearly flat up 2%; this contributed to a net loss attributable to Lineage of $63.5M or $(0.28) per share, widening sharply from $18.6M or $(0.09) due to a $35.7M unfavorable change in warrant liability. Cash and equivalents decreased to $40.8M from $45.8M, with shareholders' equity dropping to $43.3M from $77.0M.

• ·Cash used in operating activities improved to $(18.9M) from $(23.1M) YoY.
• ·Financing activities provided $27.0M in 2025 vs $35.9M in 2024.
• ·Warrant liabilities increased to $43.9M as of Dec 31, 2025 from $6.2M.
• ·Intangible assets, net decreased to $31.7M from $46.5M.
• ·Income tax benefit of $5.3M in 2025.

05-03-2026

Weave Communications, Inc. reported revenue growth of 17% YoY to $239M for the year ended December 31, 2025, from $204M in 2024, primarily driven by subscription and payment processing revenue which rose 17% to $229M. However, net loss was nearly flat at $28.1M versus $28.3M prior year, operating expenses increased 14% to $203M, and onboarding revenue declined 2% to $3.5M while gross margins remained deeply negative in onboarding (-153%) and phone hardware (-9%) segments. Total gross margin improved slightly to 72% from 71%.

• ·Stock-based compensation expense remained flat at $32.1M in 2025 vs. $32.2M in 2024.
• ·Incurrence of $1.7M in acquisition transaction costs and $0.9M in amortization of acquisition-related intangibles in 2025 (none in 2024).

05-03-2026

Regional Management Corp. entered into a Program Management Agreement (PMA) with Column National Association on March 2, 2026, establishing a new installment lending program where Column serves as lender of secured and unsecured loans in select states, and the Company acts as program manager and servicer, receiving marketing, processing, and servicing fees while paying platform and usage fees. Column retains control over underwriting, credit risk, and program oversight, with loans held for an initial period before potential sale to the Company. The PMA includes monthly financial covenants on liquidity and net worth, with an initial term ending March 31, 2031, and automatic two-year renewals unless terminated with 365 days' notice.

• ·The Company must establish and maintain a risk management program, including a compliance management system.
• ·Column holds originated loans for a specified hold period, serviced by the Company; post-hold, Column may offer to sell loans to the Company, which must purchase except in limited circumstances.
• ·Filing submitted on March 5, 2026, reporting event of March 2, 2026.

05-03-2026

Metagenomi, Inc. reported collaboration revenue declining 52% YoY to $25.2M in FY2025 from $52.3M in FY2024, primarily due to drops from Ionis (-19% to $24.6M), elimination of Moderna revenue, and Affini-T (-82% to $0.6M), resulting in a widened net loss of $87.9M versus $78.1M prior year. However, total operating expenses decreased 14% to $121.2M driven by lower R&D (-14% to $94.4M) and G&A (-16% to $26.8M), while net cash used in operations improved to $88.9M outflow from $109.1M, leading to a $14.3M net cash increase. Stockholders' equity stood at $158.6M, down from $234.9M, with total assets at $221.1M.

• ·Moderna collaboration revenue dropped to $0 from $18.7M in FY2024.
• ·Affini-T collaboration revenue declined to $0.6M from $3.1M.
• ·Cash and cash equivalents increased to $41.7M from $27.4M, but available-for-sale marketable securities fell to $119.1M from $220.9M.
• ·Stock-based compensation expense decreased to $11.9M from $16.2M.
• ·Net cash provided by investing activities was $103.5M in FY2025 versus ($88.2M) use in FY2024.

05-03-2026

On March 3, 2026, the Compensation Committee of DMC Global Inc. approved cash-based long-term incentive awards to named executive officers James O’Leary (CEO), Eric Walter (CFO), Ian Grieves (President, DynaEnergetics), and Antoine Nobili (President, NobelClad), substituting for equity awards due to insufficient shares available under the 2025 Omnibus Incentive Plan. The time-based cash awards vest one-third annually over three years, while Grieves and Nobili received performance-based cash awards tied to Adjusted EBITDA and Free Cash Flow targets (0-200% payout potential); O’Leary and Walter also got equity performance awards consistent with prior practices. No specific award values were disclosed.

• ·Cash Awards granted pursuant to new award agreements approved by the Committee.
• ·Performance goals for Grieves and Nobili based on three-year Adjusted EBITDA and Adjusted Free Cash Flow targets specific to DynaEnergetics or NobelClad.

05-03-2026

Core Laboratories Inc. adopted its First Amended and Restated Bylaws on February 27, 2026, effective under Delaware law, with updates to provisions on registered offices, stockholder meetings (annual and special), record dates, notices, quorums, proxies, and nomination procedures. The filing under Items 5.03 and 9.01 of Form 8-K on March 05, 2026, discloses no financial impacts or material changes beyond standard governance refinements. No quantitative performance metrics, improvements, declines, or flat results are reported.

• ·Bylaws permit Board to adjourn, postpone, reschedule, or cancel stockholder meetings without reason
• ·Stockholder notice for nominations/business: 90-120 days prior to annual meeting anniversary
• ·Quorum: majority voting power of outstanding shares; abstentions/broker non-votes count for quorum presence

05-03-2026

Atea Pharmaceuticals reported Q4 and FY 2025 financial results, showing cash and investments declining 33.6% to $301.8M from $454.7M amid ongoing R&D investments, with full-year R&D expenses up 2.7% to $148.0M (nearly flat YoY) and G&A down 32.6% to $32.9M, resulting in a narrower FY net loss of $158.3M versus $168.4M prior year but a wider Q4 loss of $44.9M from $33.5M. The company advanced its global Phase 3 HCV program, completing enrollment of over 880 patients in the North American C-BEYOND trial (topline mid-2026) and nearing completion in C-FORWARD (topline year-end 2026), while expanding its pipeline with HEV lead AT-587 entering clinic mid-2026. Phase 2 data reinforced BEM/RZR's potential with 98% SVR12 in per-protocol population.

• ·C-BEYOND enrollment completed December 2025; C-FORWARD enrollment expected mid-2026.
• ·AT-587 and AT-2490 showed 30-150-fold higher potency against HEV vs sofosbuvir and ribavirin in vitro.
• ·Approximately 450,000 patients/year in US/Europe with conditions risking chronic HEV (3% at risk).

05-03-2026

On March 2, 2026, the Board of Directors of German American Bancorp, Inc. approved the 2026 Management Incentive Plan applicable to all executive officers, including those named in upcoming proxy disclosures. The approval was made by non-interested directors upon recommendation from the Compensation/Human Resources Committee, with plan details provided in Exhibit 10.1. No specific performance metrics or financial impacts were disclosed in the filing.

05-03-2026

Littelfuse, Inc. (NASDAQ: LFUS) appointed Holly B. Paeper to its Board of Directors, effective March 4, 2026, and to the Technology Committee. Paeper, President of Commercial HVAC Americas at Trane Technologies, offers extensive leadership in thermal management, life sciences, and prior roles at Corning, Eaton, and Intel. The company employs approximately 17,000 global associates serving over 100,000 end customers.

• ·Paeper previously served as President of global Life Science Solutions at Trane Technologies (2021–2024) and held VP/General Manager roles in Commercial HVAC (2016–2021).
• ·Paeper serves on the board of Mitsubishi Trane HVAC US (METUS) and previously on LiquidStack (2023–2025).
• ·Paeper holds a BS in Electrical Engineering from University of Minnesota – Institute of Technology and MBA from University of Minnesota – Carlson School of Management.

05-03-2026

Net interest income rose $4.7M YoY to $51.2M for 2025, with net interest margin expanding to 3.12% from 2.73%, driven by favorable rates despite lower volumes. However, average loans declined to $1.35B from $1.43B, total interest income fell $2.0M to $87.6M, and nonperforming assets increased to $16.7M from $14.3M. Non-interest income grew 10.25% to $11.1M supported by gains on loan sales (+32%), while non-interest expenses edged up 1.49% to $42.9M.

• ·Capital ratios remain strong: Total capital 14.6% (2025) vs 15.6% (2024), all well above well-capitalized thresholds.
• ·CRE portfolio: $443M Non-Owner Occupied, $240M Owner-Occupied, with criticized loans at 1.4%-7.9% of segments.
• ·Net loan recoveries of $58k in 2025 vs net charge-offs of $100k in 2024; NCOs (annualized) 0.00% vs (0.01)%.

05-03-2026

Farmers National Banc Corp reported total assets of $5.16B at year-end 2025, up 1.5% from $5.09B in 2024, with average loans increasing 2% YoY to $3.29B at 5.82% yield and net interest income rising 11% to $145M with margin expanding to 2.95% from 2.69%. However, nonperforming assets rose 15% to $26.3M (0.50% of assets from 0.45%), nonperforming loans increased to $26.2M (0.79% of loans from 0.70%), and stockholders' equity grew to $441M amid merger integration risks with Middlefield. Quarterly cash dividends remained flat at $0.17 per share.

• ·Commercial real estate nonaccrual loans increased to $15.8M at Dec 31, 2025 from $10.6M in 2024.
• ·Loans delinquent 30-89 days rose to $17.0M (0.51% of loans) in 2025 from $13.0M (0.40%) in 2024.
• ·Allowance for credit losses covered 142% of nonaccrual loans at Dec 31, 2025, down from 162% in 2024.
• ·Total interest-bearing deposits averaged $3.41B in 2025, up from $3.26B in 2024.

05-03-2026

Lifecore Biomedical, Inc. (LFCR) reported that its Board of Directors established June 4, 2026, as the date for the 2026 Annual Meeting of Stockholders, following a fiscal year change approved on August 1, 2025, to align with the calendar year ending December 31, effective for the period from May 26, 2025, to December 31, 2025. This shifts the meeting date more than 30 days from the 2025 Annual Meeting held on October 29, 2025. Shareholder proposals and director nominations must be received by March 16, 2026, and sent to the Secretary at 3515 Lyman Blvd., Chaska, MN 55318.

• ·Fiscal year change effective for period May 26, 2025, to December 31, 2025.
• ·Proposals must comply with Rule 14a-8, Rule 14a-18, Rule 14a-19(b), Bylaws, and Delaware law.

05-03-2026

Methode Electronics reported fiscal Q3 2026 net sales of $233.7M, down 2.6% YoY from $239.9M, driven by Automotive segment declines of 8.2% to $106.2M and a sharp drop in Interface to $5.0M from $12.3M, partially offset by 9.5% growth in Industrial to $122.5M. Net loss widened to $15.9M from $14.4M, with adjusted EBITDA falling to $7.3M from $12.3M amid transformation costs and market disruptions. FY26 guidance was narrowed to $950M-$1B in sales and lowered to $58-62M adjusted EBITDA; post-quarter, the company closed the $16M sale of dataMate business and finalized sale of Harwood Heights facility.

• ·Net cash provided by operating activities Q3 FY26: $15.4M (down from $28.1M YoY)
• ·Free cash flow Q3 FY26: $10.1M (down from $19.6M YoY)
• ·9M FY26 free cash flow: $16.5M
• ·FY26 guidance: Interest expense $21-23M, Tax expense $17-21M, D&A $58-63M, Capex $24-29M
• ·Conference call scheduled for March 6, 2026 at 11:00 a.m. ET

05-03-2026

O-I Glass, Inc. announced an organizational change where Arnaud Aujouannet will cease serving as Senior Vice President and Chief Sales and Marketing Officer effective March 4, 2026. He will transition to a non-executive employee on garden leave, receiving continued salary and benefits until his employment terminates on June 30, 2026, and will be eligible for severance under the company's Amended and Restated Executive Severance Policy.

• ·Event reported on March 3, 2026; filing dated March 5, 2026
• ·Company headquartered at One Michael Owens Way, Perrysburg, Ohio 43551-2999

05-03-2026

The GEO Group, Inc. (NYSE: GEO) announced that its Chief Financial Officer, Mark Suchinski, will depart effective March 31, 2026, to relocate out-of-state and join another industry. Shayn March, Executive Vice President, Finance and Treasurer with 17 years at GEO, has been appointed as the new CFO effective April 1, 2026. Chairman and CEO George C. Zoley highlighted March's experience and expressed optimism for growth opportunities.

• ·GEO provides services in the United States, Australia, South Africa, and the United Kingdom.
• ·Announcement dated March 5, 2026.

05-03-2026

ABVC BioPharma, Inc. has issued a proxy statement for its 2026 Annual Meeting of Shareholders, to be held virtually on March 26, 2026 at 10:00 a.m. EST, with a record date of January 26, 2026 and 25,423,654 shares of Common Stock outstanding. Shareholders will vote on re-electing current director nominees for one-year terms, ratifying S&E as the independent registered public accounting firm for the year ending December 31, 2026, and approving an amendment to the Amended and Restated 2016 Equity Incentive Plan to increase authorized shares to a maximum of 15% of issued and outstanding shares inclusive of the evergreen provision. The Board unanimously recommends voting 'FOR' all proposals, with no financial performance metrics or period comparisons disclosed.

• ·Proxy submission deadline: 11:59 p.m. EST on March 25, 2026
• ·Meeting held virtually via Zoom (Meeting ID: 271 131 5701, Passcode: f3w3a6)
• ·Voting methods: Internet (www.proxyvote.com), telephone (1-800-690-6903), or mail

05-03-2026

RPM International Inc. entered into a Seventh Amendment to its revolving credit facility on February 27, 2026, extending the maturity by five years to February 27, 2031. Interest spreads are set initially at 0.0% for base rate loans and 1.00% for SOFR and RFR-based loans (with ranges of 0.0%-0.30% and 0.785%-1.30%, respectively), alongside a 0.125% facility fee (range 0.09%-0.20%), all adjustable by debt rating. The amendment retains a maximum leverage ratio covenant of 3.75:1.0 but eliminates the prior interest coverage ratio requirement.

• ·Original Credit Agreement dated October 31, 2018.
• ·Full Credit Agreement Amendment to be filed as exhibit to Form 10-Q for quarter ending February 28, 2026.
• ·Covenants include limitations on liens and asset sales/transfers.
• ·Events of default include payment defaults, covenant breaches, change of control, and ERISA events.

05-03-2026

Genco Shipping & Trading Limited executed a Sixth Amendment to its August 2021 Credit Agreement on February 27, 2026, establishing $80M in Incremental Revolving Commitments (2026 Upsize Revolving Commitments) to finance the acquisition of two 5-8 year old vessels: Genco Stars and Stripes and Genco Valkyrie (2026 Accordion Vessels). Consenting Lenders approved increasing the appraisal value threshold from 50% to 53.7% solely for these vessels, accepting pre-delivered appraisals from Fearnleys (Jan 20, 2026) and Clarksons (Jan 28, 2026). No declines or flat metrics reported in this financing update.

• ·Credit Agreement originally dated August 3, 2021; prior amendments on November 8, 2022; May 30, 2023; October 16, 2023; November 29, 2023; July 10, 2025
• ·Vessel appraisals dated January 20, 2026 (Fearnleys) and January 28, 2026 (Clarksons)

05-03-2026

Bowman Consulting Group Ltd. reported gross contract revenue of $490M for FY2025, up 14.9% YoY from $427M, with strong segment growth in Natural Resources (+27.2%), Power/Utilities & Energy (+22.7%), and Transportation (+18.2%), though Building Infrastructure grew modestly at 7.4%. Net income rose sharply to $12.8M (2.6% margin) from $3M (0.7% margin), and Adjusted EBITDA increased 22.4% to $72.9M (16.8% margin). However, acquired revenue plunged 79.4% to $8.7M, operating expenses grew to $242M, and revolving credit facility debt more than doubled to $95M from $37M.

• ·Operating income swung to $19.7M profit from $2M loss YoY.
• ·Cash and equivalents increased to $11.1M from $6.7M.
• ·Goodwill rose to $174M from $135M, reflecting acquisitions.
• ·Diluted EPS improved to $0.73 from $0.17.
• ·Total liabilities increased to $319M from $260M.

05-03-2026

Sealed Air Corporation filed an 8-K under Item 8.01 to provide Rule 135c notice on expected debt financing for its acquisition by CD&R affiliates, approved by stockholders on February 25, 2026, pursuant to the November 16, 2025 merger agreement. The financing includes a $4.3B USD senior secured term loan, $600M euro term loan, $1.15B senior secured notes, $600M euro senior secured notes, $500M senior unsecured notes, and up to $1.4B revolving credit facility, to be used for the transaction and related redemptions. Final terms remain subject to market conditions, with plans to redeem outstanding senior notes due 2027-2032 while leaving $450M of 6.875% notes due 2033 outstanding.

• ·Existing notes to be redeemed: 4.000% senior notes due 2027, 6.125% senior notes due 2028, 5.000% senior notes due 2029, 7.250% senior notes due 2031, and 6.500% senior notes due 2032.

05-03-2026

Cherry Hill Mortgage Investment Corp (CHMI) reported net income of $6.9M for the year ended December 31, 2025, down 43% YoY from $12.2M in 2024, with net income applicable to common stockholders swinging to a $3.0M loss from a $2.1M profit amid unrealized losses on derivatives and servicing assets. However, earnings available for distribution (EAD) attributable to common stockholders increased 30% YoY to $15.8M ($0.46 per diluted share from $0.40), supported by net interest income surging to $11.3M from near-zero levels due to lower interest expense. Segment results were mixed, with RMBS comprehensive income rising sharply to $16.9M from $2.1M while Servicing Related Assets declined to $8.8M from $18.6M, and net servicing income fell 6% YoY to $34.0M.

• ·Total expenses decreased 22% YoY to $14.2M from $18.3M.
• ·Accumulated other comprehensive income improved to $3.7M as of Dec 31, 2025 from a $7.3M loss.
• ·Dividends on preferred stock were $9.8M in 2025, slightly down from $10.0M in 2024.
• ·All Other segment showed comprehensive loss of $7.9M in 2025, improved from $13.2M loss in 2024.

05-03-2026

Adial Pharmaceuticals reported a reduced net loss of $7.98M for the year ended December 31, 2025, compared to $13.20M in 2024, primarily due to lower R&D expenses ($2.62M, down 19% YoY) and absence of $4.46M inducement expense. However, G&A expenses rose slightly by 2% to $5.18M, total operating expenses declined modestly to $7.80M, and significant share dilution occurred with common shares outstanding increasing over 4x to 1.11M. Cash and equivalents grew 57% to $5.88M, bolstered by $8.47M in financing activities, though operating cash use remained high at $6.49M.

• ·Total assets increased to $6.67M as of Dec 31 2025 from $5.04M as of Dec 31 2024.
• ·Equity method investment declined to $0.49M from $0.98M.
• ·Net cash used in operating activities improved slightly to $6.49M from $6.92M.
• ·Weighted average shares outstanding increased to 668,630 from 194,059; loss per share improved to $(11.93) from $(68.01).

05-03-2026

GalaxyEdge Acquisition Corp, a Cayman Islands blank check company, priced its initial public offering of 10,000,000 units at $10.00 per unit, raising $100M, with units expected to begin trading on NYSE under 'GLEDU' on March 4, 2026, and closing on March 5, 2026. The offering includes a 45-day over-allotment option for up to 1,500,000 additional units. Polaris Advisory Partners serves as sole book-running manager, with no reported declines or flat metrics in this IPO announcement.

• ·S-1 registration statement (File No. 333-290899) declared effective February 26, 2026; Post-Effective Amendments filed March 2 and 3, 2026.
• ·Target focus: business combinations in North America, South America, Europe, or Asia.
• ·Contact: (212) 574-4425

05-03-2026

urban-gro, Inc. dismissed its independent auditor Sadler, Gibb & Associates, LLC, effective February 27, 2026, and appointed Suri and Co., Chartered Accountants of India on March 3, 2026, with no disagreements or reportable events noted with the former auditor. Separately, on March 4, 2026, the company received notice from Nasdaq that it has regained compliance with the Stockholders’ Equity Requirement, Annual Meeting Requirement, and Timely Filing Requirement, following prior delinquencies and extensions. While the auditor change was clean, it follows a history of filing delays and listing issues.

• ·Sadler was engaged on May 29, 2024, and issued unqualified reports for fiscal years ended December 31, 2022, 2023, and 2024.
• ·Nasdaq previously cited non-compliance with Bid Price Rule (common stock bid price below $1.00 for 30 consecutive business days), with compliance extension to February 24, 2026.
• ·Company faced prior delisting risks due to delayed 10-K for FY 2024 and 10-Qs for Q1, Q2, and Q3 2025.

05-03-2026

Fidelis Insurance Holdings Ltd reported net income of $225.5M in 2025, up 99% YoY from $113.3M in 2024, driven by underwriting income surging to $117.2M from $8.3M and improved combined ratio of 94.8% versus 99.7%. However, gross premiums written grew modestly 7% YoY to $4.7B, net investment income declined 3% to $184.0M, and net premiums earned were nearly flat at +2% YoY to $2.3B. Operating ROAE improved to 8.5% from 5.6%, while credit ratings remained stable at A (AM Best), A- (S&P), and A3 (Moody's) across key subsidiaries.

• ·Catastrophe and large losses increased slightly to $515.5M in 2025 from $509.0M in 2024.
• ·Financing costs rose to $47.7M in 2025 from $33.8M in 2024.
• ·Weighted average diluted common shares outstanding decreased to 106.7M in 2025 from 115.6M in 2024.
• ·2023 net income included a one-time $1,639.1M net gain on distribution of The Fidelis Partnership.